New Agents for the Management of Tenosynovial Giant Cell Tumor:
A Virtual Reality Tour of CSF1 Pathway Inhibitors

Questions marked with a * are required
A 37-year-old patient with diffuse-type TGCT recently underwent arthroscopic synovectomy of her knee and she would like to know her prognosis. Which of the following statements is TRUE? 
Which of the following statements best describes the role of colony-stimulating factor 1 (CSF1) in the pathogenesis of TGCT? 
A 50-year-old man presents with recurrent diffuse-type TGCT in his left knee. He underwent arthroscopic anterior synovectomy in 2016 and an open synovectomy followed by radiation in 2018. The patient has significant swelling and pain in his knee, and he has used a wheelchair for the last 18 months. Which of the following would be the best option to manage this patient’s TGCT? 
Powered by QuestionPro